Intestinal Flora Balance Therapy Based on Probiotic Support Improves Cognitive Function and Symptoms in Patients with Alzheimer's Disease: A Systematic Review and Meta-analysis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 Aug 26

PMID 36017397

Authors

Changxing Liu

Xinyi Guo

Xiang Chang

Affiliations

Soon will be listed here.

Abstract

Objective: The clinical value of intestinal flora balance therapy based on probiotic support in improving cognitive function and symptoms of patients with Alzheimer's disease was to systematically evaluate, so as to provide evidence-based medicine basis for the promotion and use of this therapy.

Methods: The randomized controlled trials (RCTs) were searched for the improvement of cognitive function and symptoms of patients with Alzheimer's disease by intestinal flora balance therapy supported mainly by probiotics in PubMed, EMBASE, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP database, Wanfang database, and China Biomedical Literature Database (CBM) online database (RCT). Data were extracted independently by two researchers, and the literature was assessed for risk of bias according to the Cochrane Handbook 5.1.0 criteria. The data were meta-analyzed using RevMan 5.4 statistical software.

Results: Finally, 5 randomized controlled trials were included, with a total sample size of 386 cases. The results of meta-analysis showed that Chi = 13.14, df = 2, = 0.001, and = 85% showed significant heterogeneity in the inclusion of the study data. Probiotic-supported intestinal microflora balance therapy improves cognitive function in patients with Alzheimer's disease. Through meta-analysis of transient memory scores, it is concluded that intestinal flora balance therapy based on probiotic support can improve transient memory in patients with Alzheimer's disease. Meta-analysis of ADAS-COG score showed that intestinal flora balance therapy supported by probiotics could improve the cognitive function of patients with Alzheimer's disease. The ADL score was analyzed by meta, and the heterogeneity test result was Chi = 0.79, df = 1, = 0.37 > 0.05, and = 0%, indicating that the intestinal flora balance therapy supported by probiotics can improve the ability of daily living of patients with Alzheimer's disease.

Conclusion: Intestinal flora balance therapy based on probiotic support can effectively improve cognitive function, instantaneous memory, and ability of daily life in patients with Alzheimer's disease. However, more studies and long-term follow-up studies with higher methodological quality are needed to further verify.

Citing Articles

The effect of probiotics on select cognitive domains in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.

Tripathi S, Kaushik M, Dwivedi R, Tiwari P, Tripathi M, Dada R J Alzheimers Dis Rep. 2025; 8(1):1422-1433.

PMID: 40034358 PMC: 11863739. DOI: 10.1177/25424823241289039.

Mild cognitive impairment and microbiota: what is known and future perspectives.

Gallo A, Martone A, Liperoti R, Cipriani M, Ibba F, Camilli S Front Med (Lausanne). 2024; 11:1410246.

PMID: 38957302 PMC: 11217486. DOI: 10.3389/fmed.2024.1410246.

Acupuncture modulates the gut microbiota in Alzheimer's disease: current evidence, challenges, and future opportunities.

Yan L, Li H, Qian Y, Liu Q, Cong S, Dou B Front Neurosci. 2024; 18:1334735.

PMID: 38495110 PMC: 10940355. DOI: 10.3389/fnins.2024.1334735.

Retracted: Intestinal Flora Balance Therapy Based on Probiotic Support Improves Cognitive Function and Symptoms in Patients with Alzheimer's Disease: A Systematic Review and Meta-analysis.

International B Biomed Res Int. 2024; 2023:9817147.

PMID: 38188841 PMC: 10769752. DOI: 10.1155/2023/9817147.

Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential.

Qu L, Li Y, Liu F, Fang Y, He J, Ma J Aging Dis. 2023; 15(3):1108-1131.

PMID: 37728579 PMC: 11081173. DOI: 10.14336/AD.2023.0823-2.

References

Rynearson K, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P . Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention. J Exp Med. 2021; 218(4). PMC: 7931646. DOI: 10.1084/jem.20202560. View

Chia R, Sabir M, Bandres-Ciga S, Saez-Atienzar S, Reynolds R, Gustavsson E . Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021; 53(3):294-303. PMC: 7946812. DOI: 10.1038/s41588-021-00785-3. View

Theofilas P, Ehrenberg A, Dunlop S, Di Lorenzo Alho A, Nguy A, Leite R . Locus coeruleus volume and cell population changes during Alzheimer's disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2016; 13(3):236-246. PMC: 5298942. DOI: 10.1016/j.jalz.2016.06.2362. View

Nguyen H, Di Lucente J, Chen Y, Cui Y, Ibrahim R, Pennington M . Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4-mediated calcium entry in microglia. Glia. 2020; 68(11):2377-2394. PMC: 7540709. DOI: 10.1002/glia.23847. View

Staffaroni A, Asken B, Casaletto K, Fonseca C, You M, Rosen H . Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF). Alzheimers Dement. 2020; 17(4):574-583. PMC: 8044003. DOI: 10.1002/alz.12214. View

Gordon B, Blazey T, Christensen J, Dincer A, Flores S, Keefe S . Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain. 2019; 142(4):1063-1076. PMC: 6439328. DOI: 10.1093/brain/awz019. View

Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A . Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest. 1998; 78(9):1169-77. View

Chang R, Knox J, Chang J, Derbedrossian A, Vasilevko V, Cribbs D . Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease. Mol Pharm. 2017; 14(7):2340-2349. DOI: 10.1021/acs.molpharmaceut.7b00200. View

Wilcock D, Jicha G, Blacker D, Albert M, DOrazio L, Elahi F . MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimers Dement. 2021; 17(4):704-715. PMC: 8122220. DOI: 10.1002/alz.12215. View

10.

Chen X . A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome. Neural Regen Res. 2021; 16(12):2420-2421. PMC: 8374580. DOI: 10.4103/1673-5374.313044. View

11.

Cooke J, Loredo J, Liu L, Marler M, Corey-Bloom J, Fiorentino L . Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs Aging. 2006; 23(6):503-11. DOI: 10.2165/00002512-200623060-00005. View

12.

Mausbach B, Chattillion E, Ho J, Flynn L, Tiznado D, von Kanel R . Why does placement of persons with Alzheimer's disease into long-term care improve caregivers' well-being? Examination of psychological mediators. Psychol Aging. 2014; 29(4):776-86. PMC: 4267921. DOI: 10.1037/a0037626. View

13.

Lu H, Kashani A, Arfanakis K, Caprihan A, DeCarli C, Gold B . MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. Alzheimers Dement. 2021; 17(4):716-725. PMC: 8627001. DOI: 10.1002/alz.12216. View

14.

Ruan Z, Pathak D, Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N . Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 2020; 144(1):288-309. PMC: 7880668. DOI: 10.1093/brain/awaa376. View

15.

Silverman W, Krinsky-McHale S, Lai F, Rosas H, Hom C, Doran E . Evaluation of the National Task Group-Early Detection Screen for Dementia: Sensitivity to 'mild cognitive impairment' in adults with Down syndrome. J Appl Res Intellect Disabil. 2020; 34(3):905-915. PMC: 8356176. DOI: 10.1111/jar.12849. View

16.

Madhavan A, Schwarz C, Duffy J, Strand E, Machulda M, Drubach D . Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. J Alzheimers Dis. 2015; 49(3):633-43. PMC: 10038690. DOI: 10.3233/JAD-150502. View

17.

Tang X, Holland D, Dale A, Miller M . APOE Affects the Volume and Shape of the Amygdala and the Hippocampus in Mild Cognitive Impairment and Alzheimer's Disease: Age Matters. J Alzheimers Dis. 2015; 47(3):645-60. PMC: 5479937. DOI: 10.3233/JAD-150262. View

18.

Milanini B, Samboju V, Cobigo Y, Paul R, Javandel S, Hellmuth J . Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease. Neurobiol Aging. 2019; 82:69-76. PMC: 6823146. DOI: 10.1016/j.neurobiolaging.2019.07.006. View

19.

Saijo E, Metrick 2nd M, Koga S, Parchi P, Litvan I, Spina S . 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2019; 139(1):63-77. PMC: 7192393. DOI: 10.1007/s00401-019-02080-2. View

20.

Edmonds E, Delano-Wood L, Galasko D, Salmon D, Bondi M . Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):231-42. PMC: 4634634. DOI: 10.3233/JAD-150128. View